Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 5/20 | 0.34 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24630996 | 0.95 | LMNA (0.40) | SIGMAR1LMNAADRB2ADRB1KDM4E | |
| SCHEMBL24630999 | 0.85 | SIGMAR1 (0.38) | SIGMAR1ADRB2ADRB1KDM4EHTR1A | |
| SCHEMBL24630993 | 0.82 | ADRB2 (0.48) | MEN1KMT2AADRB2ADRB1HTR1A | |
| SCHEMBL22864140 | 0.81 | ADRB2 (0.49) | MEN1KMT2ALMNAADRB2ADRB1 | |
| SCHEMBL24630925 | 0.81 | ADRB2 (0.37) | MEN1KMT2AADRB2ADRB1KDM4E | |
| SCHEMBL22864136 | 0.80 | KDM4E (0.40) | SIGMAR1LMNAADRB2ADRB1KDM4E | |
| SCHEMBL24630995 | 0.80 | ADRB2 (0.31) | ADRB2ADRB1 | |
| SCHEMBL24630930 | 0.78 | ADRB2 (0.30) | ADRB2 | |
| SCHEMBL24630913 | 0.78 | ADRB2 (0.37) | MEN1KMT2AADRB2ADRB1KDM4E | |
| SCHEMBL24631034 | 0.74 | IDO1 (0.59) | ADRB2ADRB1HRH1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220315534-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315534-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRB2, ADRB1, ADRA2C | SIGMAR1 71/4885MEN1 4299/4885KMT2A 4289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.